Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
2.670
+0.070 (2.69%)
May 2, 2025, 4:00 PM EDT - Market closed
Mereo BioPharma Group Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Mereo BioPharma Group stock have an average target of 7.71, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 188.76% from the current stock price of 2.67.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mereo BioPharma Group stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +162.17% | Apr 9, 2025 |
| JP Morgan | JP Morgan | Buy Initiates $7 | Buy | Initiates | $7 | +162.17% | Mar 27, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +162.17% | Mar 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $7 | Buy | Reiterates | $7 | +162.17% | Mar 18, 2025 |
| Needham | Needham | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +162.17% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
23.67M
Revenue Next Year
36.95M
from 23.67M
Increased by 56.11%
EPS This Year
-0.05
from -0.29
EPS Next Year
-0.02
from -0.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 101.0M | 75.8M | 109.7M | ||
| Avg | 23.7M | 36.9M | 65.4M | ||
| Low | n/a | 988,751 | 18.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 220.2% | 196.8% | ||
| Avg | - | 56.1% | 77.1% | ||
| Low | - | -95.8% | -49.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.02 | 0.06 | 0.02 | ||
| Avg | -0.05 | -0.02 | -0.03 | ||
| Low | -0.07 | -0.07 | -0.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.